Skip to main content

Table 5 Information on medical therapy

From: National quality register of congenital heart diseases – Can we trust the data?

Variable

Information in Swedcon

Information in medical records

Concordance (%)

Specificity

Sensitivity

 

Number of patients with treatment

Number of patients without treatment

Number of patients with treatment

Number of patients without treatment

 

Medical treatment (pediatric)

Heart failure

5

17

8

14

86%

100%

63%

Antiarrhythmics

1

21

1

21

100%

100%

100%

Antithrombotic

14

8

15

7

86%

86%

87%

Systemic hypertension

2

20

2

20

91%

95%

50%

Pulmonary hypertension

3

19

3

19

100%

100%

100%

Immunomodulatory

0

22

0

22

100%

100%

GUCH information on treatment

Pacemaker

8

171

10

174

98%

99%

70%

Medical cardiovascular therapy

70

110

81

103

91%

97%

84%

Medical treatment (GUCH)

Sotalol

3

80

3

80

100%

100%

100%

Class I antiarrhythmic agent

1

82

1

82

100%

100%

100%

Amiodarone

1

82

0

83

99%

99%

Other antiarrhythmic

1

82

2

81

99%

100%

50%

Beta blocker

23

60

27

56

90%

96%

78%

Calcium channel blocker

6

77

10

73

95%

100%

60%

Digitalis

3

80

2

81

99%

99%

100%

Diuretics

13

70

18

65

89%

97%

61%

Nitro-glycerine

0

83

1

82

99%

100%

0%

ACEIa

11

72

12

71

96%

99%

83%

ARBb

17

66

19

64

95%

98%

84%

ASAc

24

59

29

54

89%

96%

76%

Thrombocyte inhibitor other than ASAc

4

79

3

80

94%

96%

33%

Warfarin

18

65

18

65

93%

95%

83%

NOACd

6

77

7

76

99%

100%

86%

Other agent against systemic hypertension

0

83

2

81

98%

100%

0%

Endothelin receptor antagonist

2

81

3

80

99%

100%

67%

Sildenafil

1

82

1

82

100%

100%

100%

Prostacyclin analogue

0

83

0

83

100%

100%

Other drugs against pulmonary hypertension

0

83

0

83

100%

100%

Drug against hyperlipidaemia

19

64

17

66

98%

97%

100%

Oxygen therapy

0

83

0

83

100%

100%

  1. a ACEI angiotensin-converting-enzyme inhibitor, b ARB angiotensin II receptor blockers, c ASA acetylsalicylic acid, d NOAC new oral type of anticoagulatia